AG 014

Drug Profile

AG 014

Alternative Names: AG014; Certolizumab - Intrexon; Lactococcus lactis expressing certolizumab; Lactococcus lactis secreting certolizumab

Latest Information Update: 24 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation
  • Class Anti-inflammatories; Bacteria; Fab fragments
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 22 Oct 2014 AG 014 is available for licensing as of 30 Sep 2014.
  • 16 Oct 2014 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in Belgium (PO)
  • 16 Oct 2014 ActoGeniX completes a phase I trial in healthy volunteers in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top